News

On July 30th, local time, the 76th American Clinical Chemistry Conference and Exposition of Clinical Laboratory Medicine (ADLM), which attracted global attention, was held at the McCormick Expo in Chicago, USA. The event showcased the world's most advanced technical achievements and testing equipment in the field of clinical testing, attracting tens of thousands of medical experts and industry professionals from more than 100 countries. This year, Autobio made its debut at the exhibition with its AutoLumo A6200 series of fully automated chemistry analyzers, with the objective of sharing the latest achievements in the field of in vitro diagnostics with the attendees.

The AutoLumo A6200 series is a fully automated chemiluminescent immunoassay analyzer with an online detection speed of up to 2400T/H. It features dual-core escort, high-speed detection, ease of use, expansion of interconnection, safety, and reliability.

The AutoLumo A6200 series employs a dual-core design with double backups for key components, effectively reducing the probability of downtime. A single analyzing module supports up to 5,000 human reagents, over 100 testing items, and automatic retesting. The system employs imitation water curtain vacuum cleaning and 5-step swimming magnetic separation technology, ensuring thorough cleaning and enhanced accuracy in detection. The reaction cups are automatically arranged, and the cleaning solution is designed to automatically proportion, reducing manual intervention. It can achieve speeds of up to 2400T/H for multiple chemiluminescent immunoanalyzers. It can also be used for multiple immunisation or biochemistry online, allowing for expansion into modular or TLA assembly lines.

Furthermore, this series can be paired with over 150 magnetic particle chemiluminescence detection reagents from Autobio. With a comprehensive range of products and a high degree of self-sufficiency in core raw materials, the series is particularly well-suited for use in the diagnosis of infectious diseases, tumors, thyroid disorders, sex hormones, respiratory pathogens, hypertension, and other conditions. Additionally, the series is being upgraded to include leading products in the fields of autoimmunity and allergens.

Autobio also showcased a range of strategic products, including the AutoLumo A1860 series, a fully automated chemiluminescence analyzer; the Ci-120x, a fully automated coagulation analyzer; the BC60, a new generation of fully automated blood culture system; and the MS1600, a microbial mass spectrometry detection system. Company representatives engaged with attendees, sharing insights into the latest developments in the field of testing.

At the Americas Agents Dinner, Mr. Fu Guangyu, Executive Vice President of Autobio, delivered a speech. He stated that Autobio's overseas business growth over the past year would not have been possible without the support of its agents. Autobio places a high value on the growth of the American market and has established an R&D center in North America, a pivotal move in our global expansion strategy. This also represents a significant opportunity to leverage global resources and enhance our technological innovation and product research and development capabilities. He is eager to deepen collaboration with all partners, stay abreast of the latest developments in the in vitro diagnostics industry, proactively adapt to market shifts, and foster a promising future of shared resources and mutual benefit.

Autobio is committed to the advancement of medical laboratory technology for the benefit of human health. We adhere to the principles of innovation and development, accelerate our global market expansion, provide overseas customers with superior products, and drive the evolution of medical laboratory technology.